HaluGen’s DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy Vancouver, British Columbia–(Newsfile Corp. – April 6, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry’s…


Previous articlePT238 – Kile Ortigo – Integration and Existential Exploration
Next articleMydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical